Literature DB >> 18319555

Serum level of galectin-3 in human bladder cancer.

Manabu Sakaki1, Natsuo Oka, Ryoichi Nakanishi, Kunihisa Yamaguchi, Tomoharu Fukumori, Hiro-Omi Kanayama.   

Abstract

We examine serum level of galectin-3 in patients with bladder cancer. We used serum samples of 67 patients with urological diseases and classified these patients into bladder cancer group (n=43) and control group (n=24). Galectin-3 concentration was measured by ELISA (Human Galectin-3 Assay Kit, IBL). And we selected the patient with high serum galectin-3 concentration (Urothelial Carcinoma, G3, pT3a pN0M0), we performed immunohistochemical staining with the VECTASTAIN ABC (Avidin Biotinylated enzyme Complex) system. Median value of serum galectin-3 concentration was 1068 pg/ml (range 551-2028) in the cancer group vs 584 pg/ml (range 259-1262) in controls. Serum galectin-3 concentration of the bladder cancer patients was statistically higher than that of controls (p<0.0005). There was no apparent correlation in serum galectin-3 concentration with the clinico-pathological features such as stage and grade. Higher expression of galectin-3 was observed in bladder cancer tissue than in normal bladder tissue. We suggest the measurement of serum galectin-3 is useful for diagnosis of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319555     DOI: 10.2152/jmi.55.127

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  29 in total

1.  [Molecular markers in the diagnostics and therapy of urothelial cancer].

Authors:  C Protzel; O W Hakenberg
Journal:  Urologe A       Date:  2010-11       Impact factor: 0.639

Review 2.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

Review 3.  Galectins in cancer: carcinogenesis, diagnosis and therapy.

Authors:  Ali Hasan Ebrahim; Zainab Alalawi; Leonardo Mirandola; Rahman Rakhshanda; Scott Dahlbeck; Diane Nguyen; Marjorie Jenkins; Fabio Grizzi; Everardo Cobos; Jose A Figueroa; Maurizio Chiriva-Internati
Journal:  Ann Transl Med       Date:  2014-09

4.  Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells.

Authors:  Florent Colomb; Weikun Wang; Deborah Simpson; Mudaser Zafar; Robert Beynon; Jonathan M Rhodes; Lu-Gang Yu
Journal:  J Biol Chem       Date:  2017-03-31       Impact factor: 5.157

Review 5.  Soluble IgE receptors--elements of the IgE network.

Authors:  Barbara Platzer; Floortje Ruiter; John van der Mee; Edda Fiebiger
Journal:  Immunol Lett       Date:  2011-09-06       Impact factor: 3.685

6.  Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Authors:  Matthias M Gaida; Sylvia T Bach; Frank Günther; Billur Baseras; Darjus F Tschaharganeh; Thilo Welsch; Klaus Felix; Frank Bergmann; Gertrud M Hänsch; Moritz N Wente
Journal:  Pathol Oncol Res       Date:  2011-09-12       Impact factor: 3.201

7.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 8.  Glycosylation and glycan interactions can serve as extracellular machinery facilitating clathrin-independent endocytosis.

Authors:  Mohit P Mathew; Julie G Donaldson
Journal:  Traffic       Date:  2019-02-28       Impact factor: 6.215

9.  Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer.

Authors:  Tatsuo Shimura; Masahiko Shibata; Kenji Gonda; Takahiro Nakajima; Shun Chida; Masaru Noda; Satoshi Suzuki; Izumi Nakamura; Shinji Ohki; Seiichi Takenoshita
Journal:  Biomed Rep       Date:  2016-05-30

10.  Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients.

Authors:  Hannah Barrow; Jonathan M Rhodes; Lu-Gang Yu
Journal:  Cell Oncol (Dordr)       Date:  2012-11-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.